Beta Blocker & Calcium Channel Blocker Toxicity Treatment

Five categories cause toxicologic bradycardia: beta blockers, calcium channel blockers, cardiac glycosides (digitalis), imidazoline agonists (clonidine), and cholinergic agents. Dihydropyridine calcium channel blockers typically cause reflex tachycardia rather than bradycardia. Beta blocker toxicity causes bradycardia, hypotension, hypoglycemia, hyperkalemia, and altered mental status. Calcium channel blocker toxicity presents with bradycardia, hypotension, and preserved mental status without hypoglycemia. Digitalis toxicity can cause any dysrhythmia except rapidly conducted atrial fibrillation, with classic symptoms including headache, nausea, vomiting, and visual disturbances (halos around lights). Visual changes are particularly characteristic and commonly tested.

This comprehensive lecture covers the management of three major cardiac drug overdoses. Digoxin toxicity presents with bradyarrhythmias, AV block, GI symptoms, and yellow-green halos; management includes atropine for bradycardia and Digifab (40mg neutralizes 0.5mg digoxin) for severe cases. Beta blocker overdose causes hypotension, bradycardia, and hypoglycemia; glucagon is the primary antidote (3-10mg IV), with high-dose insulin therapy for refractory cases. Calcium channel blocker overdose causes bradycardia, hypotension, and complete heart block; calcium is the primary antidote, with vasopressors and high-dose insulin for refractory cases. All three conditions share common management principles: airway assessment, IV access, cardiac monitoring, gastric decontamination within 1 hour, and identification of precipitating factors. Treatment success is indicated by heart rate >50, systolic BP >90, and improved systemic perfusion.

Both toxicities present with bradycardia, AV blocks, hypotension, and cardiogenic shock. Differentiating features include: hyperglycemia in calcium channel blocker toxicity versus hypoglycemia in beta blocker toxicity; bronchospasm occurs only with beta blockers; seizures occur only with lipophilic beta blockers like propranolol. Treatment overlaps significantly: ABCs, fluids (avoid in cardiogenic shock), atropine (transient effect). Specific antidotes differ: glucagon for beta blockers (increases cyclic AMP), calcium for calcium channel blockers (overcomes calcium blockade). Both benefit from high-dose insulin euglycemic therapy and vasopressors (epinephrine preferred over norepinephrine due to dual beta/alpha effects). IV lipid emulsion helps lipophilic agents. Refractory cases require ECMO. Verapamil/diltiazem cause worse cardiogenic shock than dihydropyridines.

A structured approach to identifying bradycardia causes uses the DIE mnemonic: Drugs (beta blockers, calcium channel blockers, digoxin, overdoses/toxicities), Ischemia (acute coronary syndrome), and Electrolytes (particularly hyperkalemia). STEMIs provide specific examples: inferior STEMIs affecting RCA supply to AV node cause transient blocks ranging from sinus bradycardia through third-degree block; anterior STEMIs affecting LAD cause wider QRS blocks arising further down conduction system with worse prognosis. Other considerations include increased ICP, spinal cord injuries causing neurogenic shock, and intra-abdominal hemorrhage causing paradoxical bradycardia. Hyperkalemia specifically causes prolonged QT intervals and bizarre rhythms, potentially progressing to torsades de pointes.

This section covers bradycardia treatment (atropine 1mg every 3-5 minutes, dopamine/epinephrine if refractory, pacing for refractory cases) and causes (AV block, medications, Cushing triad, neurogenic shock, MI, vasovagal events, sick sinus syndrome). For beta blocker and calcium channel blocker toxicity, use IV fluids, atropine, glucagon, and calcium gluconate. Key test-taking strategy: cross off AV node inhibitors in hypotensive patients.

This final major section details mechanical circulatory support principles and clinical application. Veno-arterial versus veno-venous ECMO configurations require distinct management approaches. Veno-arterial ECMO increases left ventricular afterload, requiring careful monitoring of pulmonary capillary wedge pressure (<15 mmHg) and pulmonary artery pulsatility (>10 mmHg) to prevent valve closure and pulmonary hypertension. Veno-venous ECMO maintains native left ventricular dynamics. Aspiration fraction (>60%) determines effective oxygenation in veno-venous ECMO. Regional perfusion assessment using near-infrared spectroscopy detects limb ischemia missed by global measurements. The aspiration fraction represents the percentage of native cardiac output being oxygenated by the ECMO circuit. Fever increases metabolic demand and may require increased ECMO support. Device selection depends on clinical scenario: pulmonary artery catheters for cardiogenic shock and complex assessment, echocardiography for all critically ill patients, and newer technologies for volume responsiveness. Early mechanical circulatory support within 6-12 hours of shock onset significantly improves patient outcomes.

Mechanical circulatory support devices, including ECMO and intra-aortic balloon pumps, play a critical role in emergency cardiac care by providing temporary cardiac and respiratory support for patients with cardiogenic shock, cardiac arrest, or severe heart failure. These devices can bridge patients to recovery, transplantation, or definitive treatment, with survival rates significantly improving when intervention occurs within 10 minutes of cardiac arrest (70% survival) compared to delayed intervention (3.1% survival after 40 minutes). The choice of device depends on patient condition, duration of support needed, and clinical setting, with short-term devices used for days to weeks and long-term devices for months to years.

ECMO (Extracorporeal Membrane Oxygenation) is a life support system that maintains life by performing blood circulation and gas exchange outside the body. Blood is drained through a vascular system and pumped by a mechanical pump through a membrane oxygenator, saturating hemoglobin with oxygen and removing CO2. ECMO serves as a support mechanism that does not treat the underlying cause, requiring continued treatment of the actual pathology. Indications include cardiac support for cardiogenic shock from myocardial infarction or myocarditis, and respiratory support for acute respiratory failure when lungs cannot perform gas exchange despite mechanical ventilation. Two main techniques exist: Veno-arterial (VA) ECMO for cardiac support, returning blood to the arterial system; and Veno-venous (VV) ECMO for respiratory support, returning blood through central veins.

Mechanical circulatory support devices assist the heart when it cannot pump blood effectively. Left ventricular assist devices (LVADs) are mechanical pumps that support the left ventricle in pumping blood throughout the body, used in advanced heart failure as a bridge to transplantation or as destination therapy. Intra-aortic balloon pumps provide temporary circulatory support in cardiogenic shock by inflating and deflating in synchronization with the heart's rhythm. Extracorporeal membrane oxygenation (ECMO) provides temporary heart-lung support for patients with severe heart or lung failure, pumping blood outside the body to a machine that oxygenates it before returning it to the body. These devices are used in emergency situations such as cardiac arrest, severe trauma, or as a bridge to surgery or transplantation.

Ventricular assist devices (VADs) support heart function in severe failure, sometimes keeping patients alive with completely stopped hearts. ECMO (extracorporeal membrane oxygenation) replaces heart and lung function by removing blood, adding oxygen, removing CO2, and returning blood at high pressure. Originally developed for neonatal care, ECMO became critical during the pandemic. These technologies represent frontiers in sustaining life when organs fail, pushing the boundaries of what medical science can achieve.

Metabolic emergencies require rapid recognition and targeted intervention. For severe hypoglycemia (<2.2 mmol/L) unresponsive to glucagon after 10 minutes, administer glucose 10% 150-200 ml over 15 minutes or glucose 20% 75-100 ml over 15 minutes. For severe hyperkalemia (>6.5 mmol/L) with ECG changes, give calcium chloride 10% 10 ml over 5 minutes or calcium gluconate 10% 30 ml over 10 minutes for cardiac protection, followed by insulin-glucose-salbutamol protocol. For severe hypokalemia (<2.2 mmol/L) with ECG changes, use potassium chloride with sodium chloride solution; maximum rate without ECG monitoring is 10 mmol/hour. Avoid glucose infusions which worsen hypokalemia. Always follow BNF guidelines for administration rates and monitor response.

Three major DKA treatment complications: (1) Hypokalemia causing arrhythmias (if insulin started without adequate potassium), (2) Cerebral edema (especially in children, life-threatening), and (3) Hypoglycemia (if glucose falls too rapidly). Potassium replacement is essential even when initial potassium appears normal or elevated. Cerebral edema prevention requires slow fluid administration. Hypoglycemia prevention requires adding dextrose when glucose falls below 250 mg/dL.

Complications include: hypoglycemia from rapid correction without proper monitoring, hypokalemia causing cardiac arrhythmias and arrest, cerebral edema from rapid osmolarity shifts or increased cerebral perfusion (treated with mannitol and ventilation), non-cardiogenic pulmonary edema from fluid overload, and DIC with DKA.

For hyperkalemia (high potassium), administer 2 centiliters of 50% dextrose and 9% saline per kilogram. For insulin overdose, use 5% dextrose for glucose above 250 mg/dL and 2.5% dextrose for levels above 300 mg/dL. Solution preparation involves diluting 50% dextrose in saline: 100ml of 50% dextrose in 900ml saline for 5% solution, or 50ml in 950ml for 2.5%. Post-treatment requires monitoring blood glucose every 4 hours for 12-24 hours to prevent recurrence.